Medscape is available in 5 Language Editions – Choose your Edition here.


Cholesterol Embolism

  • Author: Lisa Kirkland, MD, FACP, FCCM, MSHA; Chief Editor: Vincent Lopez Rowe, MD  more...
Updated: Aug 10, 2015


Cholesterol embolism syndrome should be suspected in a patient who develops worsening renal function, hypertension, distal ischemia, or acute multisystem dysfunction after an invasive arterial procedure. Atheroemboli may also occur spontaneously. The protean manifestations of this syndrome make the diagnosis challenging. As the population ages, the incidence of cholesterol embolism syndrome will increase.



Key components of cholesterol embolism syndrome include the following:

  • Proximal, large-caliber arterial plaque
  • Plaque rupture with embolization of debris
  • Mechanical occlusion of small arteries
  • Intense foreign-body inflammation
  • End-organ damage from mechanical obstruction
  • Inflammatory vascular changes

Any organ system, with the exception of the lungs, may be directly affected. Cholesterol embolism syndrome has two mechanisms of action.

With the first mechanism, cholesterol crystals spontaneously break off from severely atherosclerotic plaques and shower into downstream organs, occluding arterioles 100-200 μm in diameter. The crystals induce an inflammatory foreign-body reaction and adventitial fibrosis, which eventually obliterate the vessel lumen. Local vasospastic mediators compound tissue ischemia and produce progressive, irreversible organ damage.

With the second mechanism, larger cholesterol plaques break off and occlude larger arteries, causing tissue infarction with acute organ dysfunction. This can occur after local trauma to the atherosclerotic plaque, such as that caused by angiography or aortic trauma, or it can occur after destabilization of the protective clot overlying the plaque, which can occur as a result of anticoagulation.

Cholesterol crystal embolization (see the image below) occurs from the arterial system, and crystals are trapped in the arterioles, where they either immediately occlude the vessels or induce an intense inflammatory response that leads to tissue ischemia. Crystals do not travel to the lungs; however, inflammatory mediators released by ischemic tissue may result in acute lung injury.

Cholesterol crystal embolization from upstream cor Cholesterol crystal embolization from upstream coronary artery plaque after percutaneous transluminal coronary angioplasty.


Any risk factor for atherosclerotic disease is a risk factor for cholesterol embolism.

Preoperative risk factors for cholesterol embolism syndrome after coronary artery bypass surgery (CABG) include the following:

  • Age greater than 60 years
  • Hypertension
  • Cerebrovascular disease
  • Aortoiliac disease
  • Mitral annular calcification

Although the other factors have been well known for some time, it was only comparatively recently that the association between mitral annular calcification and aortic atherosclerosis was identified.

Identifying patients at risk and making efforts to minimize aortic wall trauma help reduce the chance of cholesterol embolism. The risk that cholesterol embolism will develop may be reduced by using a brachial or axillary approach in patients known to have severely ulcerated aortic plaque, using soft flexible catheters, and avoiding high-pressure jets of contrast material.



International statistics

Estimates of the incidence of cholesterol embolic disease are usually based on autopsy data. Tissue sections from patients with the following diseases or procedures indicate the incidence of atheroembolic events:

  • Aortic aneurysms (31%)
  • Abdominal aortic aneurysm repair (up to 77%)
  • Severe aortic disease (13-16%)
  • Mild aortic disease (1-2%)

Of patients undergoing angiography, 25-30% may have atheroembolic events, whereas 2.5-3% of patients who receive percutaneous transluminal coronary angioplasty (PTCA) vein grafts and 1.4-3% of patients undergoing renal artery angioplasty or cardiac catheterization have been reported to have clinical signs of atheroemboli. Cholesterol embolism syndrome has been reported as occurring months after thrombolytic therapy for stroke, but the true incidence is unknown.[1, 2]

Age and sex-related demographics

Cholesterol embolism is a disease of persons ranging from middle-aged to elderly, with a minimum age of 50 years. The risk is greater for men than it is for women.



Patients with multisystem cholesterol embolism syndrome have a poor prognosis. The mortality of acute multisystem organ failure resulting from cholesterol embolism syndrome is 58-90%. Jucgla found an overall incidence of 58% at 15 months, increasing to 65% if visceral organs were involved.[3] Preexisting chronic renal insufficiency had a relative risk of death of 4.54.

The mortality of severe cholesterol embolism is 90% at 3 months. Mild cases with renal dysfunction, with or without skin findings, have a mortality of 16%.

Cholesterol crystal showers can become stabilized, leaving patients with varying degrees of organ dysfunction. Renal function can recover if no further insults occur, even to the degree that dialysis can be discontinued. However, patients remain at risk for recurrence of emboli.


Patient Education

Patients should be educated to watch for ulcerations and infections in chronically ischemic areas, particularly feet and toes. Ischemic neuropathy may exacerbate injury and tissue loss, predisposing the patient to gangrene.

For patient education resources, see the Cholesterol Center, as well as High Cholesterol, Cholesterol Charts (What the Numbers Mean), Lifestyle Cholesterol Management, and Cholesterol Lowering Medications.

Contributor Information and Disclosures

Lisa Kirkland, MD, FACP, FCCM, MSHA Assistant Professor, Department of Internal Medicine, Division of Hospital Medicine, Mayo Clinic; Vice Chair, Department of Critical Care, ANW Intensivists, Abbott Northwestern Hospital

Lisa Kirkland, MD, FACP, FCCM, MSHA is a member of the following medical societies: American College of Physicians, Society of Hospital Medicine, Society of Critical Care Medicine

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Travis J Phifer, MD 

Travis J Phifer, MD is a member of the following medical societies: American College of Emergency Physicians, American College of Surgeons, American Medical Association, Association for Academic Surgery, Society for Academic Emergency Medicine, Society for Vascular Surgery, Society of Critical Care Medicine

Disclosure: Nothing to disclose.

Chief Editor

Vincent Lopez Rowe, MD Professor of Surgery, Program Director, Vascular Surgery Residency, Department of Surgery, Division of Vascular Surgery, Keck School of Medicine of the University of Southern California

Vincent Lopez Rowe, MD is a member of the following medical societies: American College of Surgeons, American Heart Association, Society for Vascular Surgery, Vascular and Endovascular Surgery Society, Society for Clinical Vascular Surgery, Pacific Coast Surgical Association, Western Vascular Society

Disclosure: Nothing to disclose.

  1. Oe K, Araki T, Nakashima A, Sato K, Konno T, Yamagishi M. Late onset of cholesterol crystal embolism after thrombolysis for cerebral infarction. Intern Med. 2010. 49(9):833-6. [Medline]. [Full Text].

  2. Higo S, Hirama A, Ueda K, Mii A, Kaneko T, Utsumi K. A patient with idiopathic cholesterol crystal embolization: effectiveness of early detection and treatment. J Nippon Med Sch. 2011. 78(4):252-6. [Medline].

  3. Jucgla A, Moreso F, Muniesa C. Cholesterol Embolism: Still an Unrecognized Entity with a High Mortality. J Am Acad Derm. 2006. 55:786-793.

  4. Willens HJ, Kramer HJ, Kessler KM. Transesophageal echocardiographic findings in blue toe syndrome exacerbated by anticoagulation. J Am Soc Echocardiogr. 1996 Nov-Dec. 9(6):882-4. [Medline].

  5. Fukumoto Y, Tsutsui H, Tsuchihashi M, Masumoto A, Takeshita A,. The incidence and risk factors of cholesterol embolization syndrome, a complication of cardiac catheterization: a prospective study. J Am Coll Cardiol. 2003 Jul 16. 42(2):211-6. [Medline].

  6. Acarturk E, Ozeren A, Sarica Y. Detection of aortic plaques by transesophageal echocardiography in patients with ischemic stroke. Acta Neurol Scand. 1995 Aug. 92(2):170-2. [Medline].

  7. Adler Y, Shohat-Zabarski R, Vaturi M, Shapira Y, Ehrlich S, Jortner R. Association between mitral annular calcium and aortic atheroma as detected by transesophageal echocardiographic study. Am J Cardiol. 1998 Mar 15. 81(6):784-6. [Medline].

  8. Katz ES, Tunick PA, Rusinek H, Ribakove G, Spencer FC, Kronzon I. Protruding aortic atheromas predict stroke in elderly patients undergoing cardiopulmonary bypass: experience with intraoperative transesophageal echocardiography. J Am Coll Cardiol. 1992 Jul. 20(1):70-7. [Medline].

  9. Ribakove GH, Katz ES, Galloway AC, Grossi EA, Esposito RA, Baumann FG. Surgical implications of transesophageal echocardiography to grade the atheromatous aortic arch. Ann Thorac Surg. 1992 May. 53(5):758-61; discussion 762-3. [Medline].

  10. Tenenbaum A, Garniek A, Shemesh J, Fisman EZ, Stroh CI, Itzchak Y. Dual-helical CT for detecting aortic atheromas as a source of stroke: comparison with transesophageal echocardiography. Radiology. 1998 Jul. 208(1):153-8. [Medline].

  11. Manganoni AM, Venturini M, Scolari F, Tucci G, Facchetti F, Graifemberghi S. The importance of skin biopsy in the diverse clinical manifestations of cholesterol embolism. Br J Dermatol. 2004 Jun. 150(6):1230-1. [Medline].

  12. Belenfant X, Meyrier A, Jacquot C. Supportive treatment improves survival in multivisceral cholesterol crystal embolism. Am J Kidney Dis. 1999 May. 33(5):840-50. [Medline].

  13. Masuda J, Tanigawa T, Nakamori S, Sawai T, Murata T, Ishikawa E, et al. Use of corticosteroids in the treatment of cholesterol crystal embolism after cardiac catheterization: a report of four Japanese cases. Intern Med. 2013. 52 (9):993-8. [Medline].

  14. Elinav E, Chajek-Shaul T, Stern M. Improvement in cholesterol emboli syndrome after iloprost therapy. BMJ. 2002 Feb 2. 324(7332):268-9. [Medline]. [Full Text].

  15. Hasegawa M, Sugiyama S. Apheresis in the treatment of cholesterol embolic disease. Therap Apher Dial. 2003 Aug. 7(4):435-8. [Medline].

  16. Verneuil L, Ze Bekolo R, Dompmartin A, Comoz F, Marcelli C, Leroy D. Efficiency of colchicine and corticosteroids in a leg ulceration with cholesterol embolism in a woman with rheumatoid arthritis. Rheumatology (Oxford). 2003 Aug. 42(8):1014-6. [Medline].

  17. Sevillano-Prieto ÁM, Hernández-Martínez E, Caro-Espada J, Molina-Gómez M, Gutiérrez-Martínez E, Morales-Ruiz E, et al. Cholesterol atheroembolism and combined treatment with steroids and iloprost. Nefrologia. 2012. 32 (6):824-8. [Medline].

  18. Sanai T, Matsui R, Hirano T. LDL apheresis for cholesterol embolism following coronary artery bypass graft surgery--a case report. Angiology. 2006 May-Jun. 57(3):379-82. [Medline].

  19. Lowe HC, Houser SL, Aretz T, MacNeill BD, Oesterle SN, Palacios IF. Significant atheromatous debris following uncomplicated vein graft direct stenting: evidence supporting routine use of distal protection devices. J Invasive Cardiol. 2002 Oct. 14(10):636-9. [Medline].

  20. Carroccio A, Olin JW, Ellozy SH, Lookstein RA, Valenzuela R, Minor ME. The role of aortic stent grafting in the treatment of atheromatous embolization syndrome: results after a mean of 15 months follow-up. J Vasc Surg. 2004 Sep. 40(3):424-9. [Medline].

  21. Brown PJ, Zirwas MJ, English JC 3rd. The purple digit: an algorithmic approach to diagnosis. Am J Clin Dermatol. 2010. 11(2):103-16. [Medline].

  22. Frank RD, Velden J. Images in clinical medicine. Cholesterol emboli after coronary bypass surgery. N Engl J Med. 2011 Jan 20. 364(3):265. [Medline].

  23. Hirano Y, Ishikaw K. Cholesterol Embolization Syndrome: How to Recognize and Prevent This Potentially Catastrophic Iatrogenic Disease. Int Med. 2005. 44:1209-1210.

  24. Keen RR, McCarthy WJ, Shireman PK, Feinglass J, Pearce WH, Durham JR. Surgical management of atheroembolization. J Vasc Surg. 1995 May. 21(5):773-80; discussion 780-1. [Medline].

  25. Kirkland L. Cholesterol embolism in intensive care patients. J Intensive Care Med. 1993. 7(3):12-21.

  26. Kolh PH, Torchiana DF, Buckley MJ. Atheroembolization in cardiac surgery. The need for preoperative diagnosis. J Cardiovasc Surg (Torino). 1999 Feb. 40(1):77-81. [Medline].

  27. Kronzon I, Saric M. Cholesterol embolization syndrome. Circulation. 2010 Aug 10. 122(6):631-41. [Medline].

  28. Maki T, Izumi C, Miyake M, Izumi T, Takahashi S, Himura Y, et al. Cholesterol embolism after cardiac catheterization mimicking infective endocarditis. Intern Med. 2005 Oct. 44(10):1060-3. [Medline].

  29. Resnik KS. Intravascular cholesterol clefts as an incidental finding: cholesterol embolism or not?. Am J Dermatopathol. 2003 Dec. 25(6):497-9. [Medline].

  30. Vayssairat M, Chakkour K, Gouny P, Nussaume O. Atheromatous embolisms and cholesterol embolisms: medical treatment [French]. J Mal Vasc. 1996. 21 Suppl A:97-9. [Medline].

Cholesterol crystal embolization from upstream coronary artery plaque after percutaneous transluminal coronary angioplasty.
Necrosis of the abdominal wall in a patient with cholesterol embolism syndrome who received anticoagulation.
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.